New Treatment Methods of Sarcoidosis: Narrative Review

Multiple organs are affected by the systemic, granulomatous disease known as sarcoidosis, which has an unpredictable clinical course and an unclear etiology. Systemic therapy is required for approximately 50% of patients with sarcoidosis to treat their illness. The usual first-line treatment for sarcoidosis is oral glucocorticoids. Long-term high-dose use may cause significant morbidity in patients over time. We searched the PubMed database for articles about randomized controlled trials involving novel treatments for sarcoidosis conducted over ten years between 2012 and 2021. We looked for information on novel treatments and strategies for treating pulmonary sarcoidosis. Out of the 26 entries, the search yielded, we chose 11 studies that we thought were pertinent and served as the foundation for this analysis. (("Sarcoidosis treatment"[Mesh]) AND "Pulmonary sarcoidosis"[Mesh]) were the search terms used. Diagnosing sarcoidosis, developing therapeutic behavior, overseeing long-term treatment, and ensuring patient compliance are all very challenging. Although it is difficult to predict how the disease will progress, more than half of the cases have the possibility of remission. Multidisciplinary studies are still required to test new drugs.